Francis Chou Chou Associates Management
Francis Chou is the founder of Chou Associates Management and a Canadian value investor known for deep-value and special-situation securities. His funds have historically owned a mix of equities and distressed or complex instruments when prices offered a margin of safety. Chou’s annual reports are read for candid discussion of mistakes, opportunities, and long-term results.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$8.98M |
| 2 |
Bausch Health
BHC
|
+$8.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nokia
NOK
|
+$9M |
| 2 |
Citigroup
C
|
+$6.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.96% |
| 2 | Financials | 26.59% |
| 3 | Consumer Discretionary | 7.73% |
| 4 | Materials | 7.18% |
| 5 | Technology | 4.03% |
Similar funds
Francis Chou's Q2 2017 Portfolio in Review
As of Q2 2017, Francis Chou held 27 positions worth $324M, up 7.4% from $301M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Trading was light in Q2 2017: portfolio turnover was 0%. Francis Chou opened no new positions and made no exits, leaving the 27-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- Francis Chou added most to Teva Pharmaceuticals in Q2 2017, an estimated $8.98M increase.
- Francis Chou's biggest Q2 2017 reduction was Nokia, cutting an estimated $9M.
- Francis Chou's ten largest holdings make up 78% of its $324M portfolio in Q2 2017.
- Francis Chou opened 0 new positions and closed 0 in Q2 2017.
- Francis Chou's portfolio value rose 7.4% quarter-over-quarter to $324M.
Based on Chou Associates Management's 13F filing for Q2 2017, filed 15 Aug 2017.